Healthcare Professionals > Oncotype DX Breast Recurrence Score

How to interpret Oncotype DX® test results?

For your patients with HR+, HER2-, early-stage, invasive breast cancer

The Oncotype DX Breast Recurrence Score® report provides three points of clarity to aid in treatment decisions as to whether adjuvant chemotherapy is needed or not for node-negative and node-positive (N1: up to 3 positive lymph nodes), hormone receptor-positive, HER2-negative, early-stage breast cancer patients.

3 pieces of information provided by the test

1

Recurrence Score® result

This number, between 0 and 100, is calculated by measuring the activity of specific genes in the breast cancer tissue. The Recurrence Score result is used to predict the risk of the breast cancer returning at a distant site and whether chemotherapy may help reduce the risk.1-5

2

Distant recurrence riska

This percentage indicates the risk that the breast cancer will come back somewhere else in the body, “distant recurrence,” within 9 years (node-negative)1,6 or 5 years (node-positive)4,7,8 when treated with hormonal therapy alone for 5 years.

3

Absolute chemotherapy benefita

This percentage indicates the benefit expected for the Recurrence Score group from adding chemotherapy to hormonal therapy in order to reduce the risk of cancer recurrence or death.2-4, 6-8

a These results are valid in HR+, HER2-, early-stage, invasive breast cancer patients treated with 5 years of endocrine therapy.

Explore the patient reports

IBC_Node_Negative_Sample_Report_page_1
START REPORT GUIDE
Report Image
START REPORT GUIDE
IBC_Node_Negative_Sample_Report_page_3
START REPORT GUIDE
Example of an Oncotype DX patient sample report
START REPORT GUIDE
Example of an Oncotype DX patient sample report page 2
START REPORT GUIDE

Contact Us